Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases

ConclusionsSRS in combination with tucatinib, capecitabine, and trastuzumab appears to be a safe and feasible treatment for HER2  + brain metastases. Further prospective evaluation of potential synergistic effects is warranted.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research